Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Mylan Pharmaceuticals' abbreviated new drug application (ANDA) for Pramipexole Dihydrochloride tablets, 0.125mg, 0.25mg, 0.5mg, 1mg and 1.5mg, the generic version of Boehringer Ingelheim's Mirapex tablets.
Subscribe to our email newsletter
Pramipexole Dihydrochloride tablets are used to treat signs and symptoms of Parkinson’s disease and for the treatment of Restless Legs Syndrome (RLS).
Mylan Pharmaceuticals has received final FDA approval for the 0.75 mg strength of Pramipexole Dihydrochloride tablets on 9 April 2010.
All strengths of the product are available for immediate shipment.